AOD 9604

386264-39-7

C78H125N23O23S2

1817.0974

Polypeptide

Synthetic hGH fragment 177–191 (lipolytic peptide, 15-amino-acid cyclic)

Research compound — Not FDA approved. Phase 2b obesity trials completed, not advanced.

A synthetic 15-amino-acid peptide (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, cyclized via Cys-Cys disulfide bond) derived from the C-terminal region (amino acids 177–191) of human growth hormone. AOD-9604 mimics the fat-metabolizing domain of hGH without stimulating IGF-1 or cell proliferation. It stimulates lipolysis via β3-adrenergic receptors and inhibits lipogenesis, producing selective fat reduction.

AOD-9604 is a lipolytic peptide fragment, not a traditional receptor agonist. Functional lipolytic activity is observed at micromolar concentrations in adipocyte assays. Does not bind GHR.

Ng FM, et al. J Endocrinol. 2000;165(3):595–605. Heffernan MA, et al. Am J Physiol Endocrinol Metab. 2000;279(3):E501–E507.DOI

ACTRN12605000111673

PubChem

J Endocrinol: Ng FM et al. (2000) — Metabolic studies; ANZCTR: Phase 2b obesity trial

AOD-9604 is NOT FDA-approved or EMA-approved. Phase 2b clinical trials for obesity were completed but the program was not advanced to Phase 3. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.